India, Nov. 13 -- Equillium, Inc., (EQ), a clinical-stage biotechnology company, reported a wider loss in its third quarter compared to last year, mainly due to higher research & development expenses.
The company recorded a net loss of $4.583 million, or $0.04 per share, as against the year-ago loss of $4.230 million, or $0.06 per share.
Research and development expenses for the quarter rose to $2.488 million from $1.301 million last year.
General & administrative expenses, on the contrary, were brought down to $2.6 million from $3.3 million in the prior year's third quarter.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
In the after-hours activity Thursday, Equillium's shares were gaining 1.52 pe...